HBRM Herborium Group Inc (PK)

Herborium Group, Inc., (PINKSHEETS: HBRM), a Botanical Therapeutics™ company (www.herborium.com), today announced that it has been selected to provide the editorial on alternative acne treatment for National Association of Primary Care (NAPC) Review, Spring 2011 edition.

"Exposure in such a prestigious medical review to tens-of-thousands of U.K. general practitioners and dermatologists is a significant boost in Herborium's European brand building efforts, as well as promising acceleration of sales; it also advances the company's goal to become the worldwide leader in natural medicine," commented Dr. Agnes P. Olszewski, Herborium's president and chief executive officer. "The Review is distributed to 36,000 general practitioners and almost 2,000 dermatologists and dermatological groups."

The high-profile exposure comes at a most advantageous time, as AcnEase, (www.acnease.com) Herborium's all botanical, clinically tested acne and Rosacea treatment continues to grow as the treatment of choice in the U.K. and EU. Since general practitioners and dermatologists can operate their own pharmacies on premises and sell both prescriptive drugs as well as supplements, and natural medicines Herborium expects a further growth in sales as a result of the Editorial.

Currently, the only class of FDA approved drug to treat the cause of acne is isotretinoin. Manufactured by Hoffman La-Roche and marketed under the trade name Accutane in the U.S., and Roaccutane in Europe, this drug class was recently taken off the market due to the high number of severe side effects and the pending class-action lawsuits.

AcnEase represents a safe, effective, and natural alternative for treatment and prevention of acne.

The Spring 2011 edition of The NAPC Review is solely devoted to Acne etiology and treatments and is co-sponsored by the British Skin Foundation and the British Association of Dermatologists. The NAPC Review is sent to every General Practitioner and every Dermatologist in Great Britain effectively covering all doctors who treat patients with acne and Rosacea. Herborium's clinically tested botanical acne medicine, AcnEase, currently being sold in the U.K. since 2004, was cited as a reason for Herborium's selection.

About Herborium Group, Inc. Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanically based medicinal products to consumers and healthcare professionals. The Company's business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. For more information, please visit www.herborium.com and www.acnease.com.

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

Company Contact: Steve Haag Investor Relations (832) 413-6206